Guidance on the use of glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary

integrated care boards, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 3 months of its date of publication. 7.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal guidance recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 2 months of the first publication of the 7.3 When NICE recommends a treatment 'as an option', the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has acute coronary syndromes and the healthcare professional responsible for their care thinks that glycoprotein (GP) IIb or IIIa inhibitors is the right treatment, they should be available for use, in line with NICE's recommendations. 7.4 All clinicians who treat people with an acute coronary syndrome (ACS) should review their current policies and practice in line with the guidance set out in section 1. 7.5 Local guidelines or care pathways, particularly those on the management of patients with unstable angina or
